Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Obesity Surgery
Published in: Obesity Surgery 10/2021

01-10-2021 | Obesity | Review

Are the Changes in Gastrointestinal Hormone Secretion Necessary for the Success of Bariatric Surgery? A Critical Review of the Literature

Authors: Charalampos Lampropoulos, Theodoros Alexandrides, Stylianos Tsochatzis, Dimitrios Kehagias, Ioannis Kehagias

Published in: Obesity Surgery | Issue 10/2021

Login to get access

Abstract

Ghrelin, glucagon-like peptide-1 (GLP-1), and peptide YY (PYY) are involved in energy balance regulation and glucose homeostasis. Obesity is characterized by lower fasting levels and blunted postprandial responses of ghrelin, GLP-1, and possibly PYY. Both Roux-en-Y gastric bypass (RYGB) and sleeve gastrectomy (SG) have been shown to increase postprandial GLP-1 and PYY levels. Human studies have shown that enhanced postprandial GLP-1 and PYY release are associated with favorable weight loss outcomes after RYGB. However, studies in knockout mice have shown that GI hormones are not required for the primary metabolic effects of bariatric surgery. Here, we summarize the complex interaction between obesity, bariatric surgery, and GI hormones in order to determine the exact role of GI hormones in the success of bariatric surgery.

Graphical abstract

Literature
1.
Purnell JQ. Definitions, classification, and epidemiology of obesity. 2018 Apr 12. In: Feingold KR, Anawalt B, Boyce A, Chrousos G, de Herder WW, Dungan K, Grossman A, Hershman JM, Hofland J, Kaltsas G, Koch C, Kopp P, Korbonits M, Mclachlan R, Morley JE, New M, Purnell J, Singer F, Stratakis CA, Trence DL, Wilson DP, editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc; 2000.
2.
3.
Pucci A, Batterham RL. Mechanisms underlying the weight loss effects of RYGB and SG: similar, yet different. J Endocrinol Investig. 2019;42(2):117–28.CrossRef
4.
Latorre R, Sternini C, De Giorgio R, et al. Enteroendocrine cells: a review of their role in brain-gut communication. Neurogastroenterol Motil. 2016;28(5):620–30.PubMedCrossRef
5.
Ionut V, Burch M, Youdim A, et al. Gastrointestinal hormones and bariatric surgery-induced weight loss. Obesity (Silver Spring). 2013;21(6):1093–103.CrossRef
6.
Verhulst PJ, Depoortere I. Ghrelin’s second life: from appetite stimulator to glucose regulator. World J Gastroenterol. 2012;18(25):3183–95.PubMedPubMedCentral
7.
Goebel-Stengel M, Hofmann T, Elbelt U, et al. The ghrelin activating enzyme ghrelin-O-acyltransferase (GOAT) is present in human plasma and expressed dependent on body mass index. Peptides. 2013;43:13–9.PubMedCrossRef
8.
9.
Cowley MA, Smith RG, Diano S, et al. The distribution and mechanism of action of ghrelin in the CNS demonstrates a novel hypothalamic circuit regulating energy homeostasis. Neuron. 2003;37(4):649–61.PubMedCrossRef
10.
Kokkinos A, Tsilingiris D, le Roux CW, et al. Will medications that mimic gut hormones or target their receptors eventually replace bariatric surgery? Metabolism. 2019;100:153960.PubMedCrossRef
11.
Steinert RE, Feinle-Bisset C, Asarian L, et al. Ghrelin, CCK, GLP-1, and PYY(3-36): secretory controls and physiological roles in eating and glycemia in health, obesity, and after RYGB. Physiol Rev. 2017;97(1):411–63.PubMedCrossRef
12.
Cummings DE, Purnell JQ, Frayo RS, et al. A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans. Diabetes. 2001;50(8):1714–9.PubMedCrossRef
13.
Koliaki C, Kokkinos A, Tentolouris N, et al. The effect of ingested macronutrients on postprandial ghrelin response: a critical review of existing literature data. Int J Pept. 2010;2010:710852.PubMedPubMedCentralCrossRef
14.
Druce MR, Wren AM, Park AJ, et al. Ghrelin increases food intake in obese as well as lean subjects. Int J Obes. 2005;29(9):1130–6.CrossRef
15.
16.
Tasyurek HM, Altunbas HA, Balci MK, et al. Incretins: their physiology and application in the treatment of diabetes mellitus. Diabetes Metab Res Rev. 2014;30(5):354–71.PubMedCrossRef
17.
Elliott RM, Morgan LM, Tredger JA, et al. Glucagon-like peptide-1 (7-36)amide and glucose-dependent insulinotropic polypeptide secretion in response to nutrient ingestion in man: acute post-prandial and 24-h secretion patterns. J Endocrinol. 1993;138(1):159–66.PubMedCrossRef
18.
Lean ME, Malkova D. Altered gut and adipose tissue hormones in overweight and obese individuals: cause or consequence? Int J Obes. 2016;40(4):622–32.CrossRef
19.
20.
Glavas MM, Grayson BE, Allen SE, et al. Characterization of brainstem peptide YY (PYY) neurons. J Comp Neurol. 2008;506(2):194–210.PubMedCrossRef
21.
Batterham RL, Bloom SR. The gut hormone peptide YY regulates appetite. Ann N Y Acad Sci. 2003;994:162–8.PubMedCrossRef
22.
Batterham RL, Cowley MA, Small CJ, et al. Gut hormone PYY(3-36) physiologically inhibits food intake. Nature. 2002;418(6898):650–4.PubMedCrossRef
23.
Batterham RL, Cohen MA, Ellis SM, et al. Inhibition of food intake in obese subjects by peptide YY3-36. N Engl J Med. 2003;349(10):941–8.PubMedCrossRef
24.
Chaudhri O, Small C, Bloom S. Gastrointestinal hormones regulating appetite. Philos Trans R Soc Lond Ser B Biol Sci. 2006;361(1471):1187–209.CrossRef
25.
26.
Angrisani L, Santonicola A, Iovino P, et al. Bariatric Surgery Worldwide 2013. Obes Surg. 2015;25(10):1822–32.PubMedCrossRef
27.
Ali M, El Chaar M, Ghiassi S. Rogers AM; American Society for Metabolic and Bariatric Surgery Clinical Issues Committee. American Society for Metabolic and Bariatric Surgery updated position statement on sleeve gastrectomy as a bariatric procedure. Surg Obes Relat Dis. 2017;13(10):1652–7.PubMedCrossRef
28.
Peterli R, Wölnerhanssen BK, Peters T, et al. Effect of laparoscopic sleeve gastrectomy vs laparoscopic Roux-en-Y gastric bypass on weight loss in patients with morbid obesity: the SM-BOSS randomized clinical trial. JAMA. 2018;319(3):255–65.PubMedPubMedCentralCrossRef
29.
30.
Malin SK, Kashyap SR. Differences in weight loss and gut hormones: Roux-en-Y gastric bypass and sleeve gastrectomy surgery. Curr Obes Rep. 2015;4(2):279–86.PubMedCrossRef
31.
Makaronidis JM, Batterham RL. Potential mechanisms mediating sustained weight loss following Roux-en-Y gastric bypass and sleeve gastrectomy. Endocrinol Metab Clin N Am. 2016;45(3):539–52.CrossRef
32.
Pournaras DJ, Le Roux CW. The effect of bariatric surgery on gut hormones that alter appetite. Diabetes Metab. 2009;35(6 Pt 2):508–12.PubMedCrossRef
33.
Xu HC, Pang YC, Chen JW, et al. Systematic review and meta-analysis of the change in ghrelin levels after Roux-en-Y gastric bypass. Obes Surg. 2019;29(4):1343–51.PubMedCrossRef
34.
Oliván B, Teixeira J, Bose M, et al. Effect of weight loss by diet or gastric bypass surgery on peptide YY3-36 levels. Ann Surg. 2009;249(6):948–53.PubMedCrossRef
35.
Peterli R, Wölnerhanssen B, Peters T, et al. Improvement in glucose metabolism after bariatric surgery: comparison of laparoscopic Roux-en-Y gastric bypass and laparoscopic sleeve gastrectomy: a prospective randomized trial. Ann Surg. 2009;250(2):234–41.PubMedCrossRef
36.
Peterli R, Steinert RE, Woelnerhanssen B, et al. Metabolic and hormonal changes after laparoscopic Roux-en-Y gastric bypass and sleeve gastrectomy: a randomized, prospective trial. Obes Surg. 2012;22(5):740–8.PubMedPubMedCentralCrossRef
37.
Nosso G, Griffo E, Cotugno M, et al. Comparative effects of Roux-en-Y gastric bypass and sleeve gastrectomy on glucose homeostasis and incretin hormones in obese type 2 diabetic patients: a one-year prospective study. Horm Metab Res. 2016;48(5):312–7.PubMedCrossRef
38.
McCarty TR, Jirapinyo P, Thompson CC. Effect of sleeve gastrectomy on ghrelin, GLP-1, PYY, and GIP gut hormones: a systematic review and meta-analysis. Ann Surg. 2020;272(1):72–80.PubMedCrossRef
39.
Alamuddin N, Vetter ML, Ahima RS, et al. Changes in fasting and prandial gut and adiposity hormones following vertical sleeve gastrectomy or Roux-en-Y-Gastric bypass: an 18-month prospective study. Obes Surg. 2017;27(6):1563–72.PubMedCrossRef
40.
41.
Chronaiou A, Tsoli M, Kehagias I, et al. Lower ghrelin levels and exaggerated postprandial peptide-YY, glucagon-like peptide-1, and insulin responses, after gastric fundus resection, in patients undergoing Roux-en-Y gastric bypass: a randomized clinical trial. Obes Surg. 2012;22(11):1761–70.PubMedCrossRef
42.
Jirapinyo P, Jin DX, Qazi T, et al. A meta-analysis of GLP-1 after Roux-En-Y gastric bypass: impact of surgical technique and measurement strategy. Obes Surg. 2018;28(3):615–26.PubMedCrossRef
43.
44.
Min T, Prior SL, Churm R, et al. Effect of laparoscopic sleeve gastrectomy on static and dynamic measures of glucose homeostasis and incretin hormone response 4-years post-operatively. Obes Surg. 2020;30(1):46–55.PubMedCrossRef
45.
Harvey EJ, Arroyo K, Korner J, et al. Hormone changes affecting energy homeostasis after metabolic surgery. Mt Sinai J Med. 2010;77(5):446–65.PubMedCrossRef
46.
Yan W, Polidori D, Yieh L, et al. Effects of meal size on the release of GLP-1 and PYY after Roux-en-Y gastric bypass surgery in obese subjects with or without type 2 diabetes. Obes Surg. 2014;24(11):1969–74.PubMedCrossRef
47.
Ramón JM, Salvans S, Crous X, et al. Effect of Roux-en-Y gastric bypass vs sleeve gastrectomy on glucose and gut hormones: a prospective randomised trial. J Gastrointest Surg. 2012;16(6):1116–22.PubMedCrossRef
48.
Nannipieri M, Baldi S, Mari A, et al. Roux-en-Y gastric bypass and sleeve gastrectomy: mechanisms of diabetes remission and role of gut hormones. J Clin Endocrinol Metab. 2013;98(11):4391–9.PubMedCrossRef
49.
Chambers AP, Kirchner H, Wilson-Perez HE, et al. The effects of vertical sleeve gastrectomy in rodents are ghrelin independent. Gastroenterology. 2013;144(1):50–52.e5.PubMedCrossRef
50.
Wilson-Pérez HE, Chambers AP, Ryan KK, et al. Vertical sleeve gastrectomy is effective in two genetic mouse models of glucagon-like peptide 1 receptor deficiency. Diabetes. 2013;62(7):2380–5.PubMedPubMedCentralCrossRef
51.
Ye J, Hao Z, Mumphrey MB, et al. GLP-1 receptor signaling is not required for reduced body weight after RYGB in rodents. Am J Phys Regul Integr Comp Phys. 2014;306(5):R352–62.
52.
Boland B, Mumphrey MB, Hao Z, et al. The PYY/Y2R-deficient mouse responds normally to high-fat diet and gastric bypass surgery. Nutrients. 2019;11(3):585.PubMedCentralCrossRef
53.
le Roux CW, Welbourn R, Werling M, et al. Gut hormones as mediators of appetite and weight loss after Roux-en-Y gastric bypass. Ann Surg. 2007;246(5):780–5.PubMedCrossRef
54.
Dirksen C, Jørgensen NB, Bojsen-Møller KN, et al. Gut hormones, early dumping and resting energy expenditure in patients with good and poor weight loss response after Roux-en-Y gastric bypass. Int J Obes. 2013;37(11):1452–9.CrossRef
55.
de Hollanda A, Jiménez A, Corcelles R, et al. Gastrointestinal hormones and weight loss response after Roux-en-Y gastric bypass. Surg Obes Relat Dis. 2014;10(5):814–9.PubMedCrossRef
56.
de Hollanda A, Casals G, Delgado S, et al. Gastrointestinal hormones and weight loss maintenance following Roux-en-Y gastric bypass. J Clin Endocrinol Metab. 2015;100(12):4677–84.PubMedCrossRef
57.
Santo MA, Riccioppo D, Pajecki D, et al. Weight regain after gastric bypass: influence of gut hormones. Obes Surg. 2016;26(5):919–25.PubMedCrossRef
58.
Sima E, Webb DL, Hellström PM, et al. Non-responders after gastric bypass surgery for morbid obesity: peptide hormones and glucose homeostasis. Obes Surg. 2019;29(12):4008–17.PubMedCrossRef
59.
Kittah E, Camilleri M, Jensen MD, et al. A pilot study examining the effects of GLP-1 receptor blockade using exendin-(9,39) on gastric emptying and caloric intake in subjects with and without bariatric surgery. Metab Syndr Relat Disord. 2020;18(9):406–12.PubMedCrossRefPubMedCentral
60.
Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, McGowan BM, Rosenstock J, Tran MTD, Wadden TA, Wharton S, Yokote K, Zeuthen N, Kushner RF; STEP 1 Study Group. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989. https://​doi.​org/​10.​1056/​NEJMoa2032183
61.
Rye P, Modi R, Cawsey S, et al. Efficacy of high-dose liraglutide as an adjunct for weight loss in patients with prior bariatric surgery. Obes Surg. 2018;28(11):3553–8.PubMedCrossRef
62.
Svane MS, Jørgensen NB, Bojsen-Møller KN, et al. Peptide YY and glucagon-like peptide-1 contribute to decreased food intake after Roux-en-Y gastric bypass surgery. Int J Obes. 2016;40(11):1699–706.CrossRef
63.
Williams DL, Baskin DG, Schwartz MW. Leptin regulation of the anorexic response to glucagon-like peptide-1 receptor stimulation. Diabetes. 2006;55(12):3387–93.PubMedCrossRef
64.
Nielsen MS, Ritz C, Wewer Albrechtsen NJ, et al. Oxyntomodulin and glicentin may predict the effect of bariatric surgery on food preferences and weight loss. J Clin Endocrinol Metab. 2020;105(4):dgaa061.PubMedCrossRef
65.
Patrício BG, Morais T, Guimarães M, et al. Gut hormone release after gastric bypass depends on the length of the biliopancreatic limb. Int J Obes. 2019;43(5):1009–18.CrossRef
Metadata
Title
Are the Changes in Gastrointestinal Hormone Secretion Necessary for the Success of Bariatric Surgery? A Critical Review of the Literature
Authors
Charalampos Lampropoulos
Theodoros Alexandrides
Stylianos Tsochatzis
Dimitrios Kehagias
Ioannis Kehagias
Publication date
01-10-2021
Publisher
Springer US
Published in
Obesity Surgery / Issue 10/2021
Print ISSN: 0960-8923
Electronic ISSN: 1708-0428
DOI
https://doi.org/10.1007/s11695-021-05568-7

Other articles of this Issue 10/2021

Obesity Surgery 10/2021 Go to the issue

Original Contributions

Comparison of Bioelectrical Impedance Analysis and Computed Tomography on Body Composition Changes Including Visceral Fat After Bariatric Surgery in Asian Patients with Obesity

Correction

Correction to: Transcutaneous Electrical Acupoint Stimulation Combined with Dexamethasone and Tropisetron Prevents Postoperative Nausea and Vomiting in Female Patients Undergoing Laparoscopic Sleeve Gastrectomy: a Prospective, Randomized Controlled Trial

Original Contributions

The Outcomes of Laparoscopic Biliopancreatic Diversion with Duodenal Switch on Gastro-esophageal Reflux Disease: the Mayo Clinic Experience

Review

A Systematic Review of Genetic Correlates of Weight Loss After Bariatric Surgery

Letter to the Editor

Obesity and COVID-19: Take Two—Has Our Saw Been Adequately Sharpened?

Original Contributions

30-Day Morbidity and Mortality of Bariatric Surgery During the COVID-19 Pandemic: a Multinational Cohort Study of 7704 Patients from 42 Countries